MicroRNA and their potential in ovarian cancer diagnostics: Current state and possible future

Authors: Luděk Záveský 1;  Eva Jandáková 2;  Milada Kohoutová 1
Authors‘ workplace: Ústav biologie a lékařské genetiky 1. LF UK a VFN, Praha 1;  Ústav patologie LF MU a Fakultní nemocnice Brno 2
Published in: Prakt Gyn 2012; 16(2-4): 59-65
Category: Oncogynecology: Review Article


Epithelial ovarian cancer is the most fatal gynecologic cancer. Recent studies suggest an extraovarian origin for this disease. However, there is lack of information on exact etiology of ovarian cancer, and screening markers are also lacking. Non-coding RNA, particularly microRNAs are currently intensively investigated. They may be implicated in various cellular processes and regulate the gene expression at post-transcriptional level. In carcinogenesis, they may be involved as well, e.g. as tumor suppressors, or oncogenes. There have been identified expression profiles of microRNAs for various types of samples in ovarian cancer, however no expression profile is currently available for use in clinical diagnosis of ovarian cancer. Analyses of non-invasively collected material (e.g. urine, saliva) and further analyses of serum, or blood may provide basis for establishment of better diagnostic tools. We reviewed the studies on microRNAs shown to be deregulated in ovarian cancer, and coming from tumor tissues, plasma exosomes, serum, whole blood, and differing also between recurrent vs. primary ovarian cancer tissues. Function of particular microRNA is known partially only in several cases; however, for many microRNAs an elucidation of their functional role remains the goal for future investigations. MicroRNAs thus may stand at the beginning of novel diagnostic and therapeutic tools for ovarian cancer and other malignancies.

Key words:
ovarian cancer – diagnostics of ovarian cancer – microRNA – markers of adeno­carcinoma – adeno- ­carcinoma


1. Kurman RJ, Shih IM. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-Shifting the paradigm. Hum Pathol 2011; 42(7): 918–931.

2. Gates MA, Rosner BA, Hecht JL et al. Risk Factors for Epithelial Ovarian Cancer by Histologic Subtype. Am J Epidemiol 2010; 171(1): 45–53.

3. Cramer DW. The Epidemiology of Endometrial and Ovarian Cancer. Hematology-Oncology Clinics of North America 2012; 26(1): 1–12.

4. Gram IT, Lukanova A, Brill I et al. Cigarette smoking and risk of histological subtypes of epithelial ovarian cancer in the EPIC cohort study. Int J Cancer 2012; 130(9): 2204–2210.

5. Jemal A, Siegel R, Xu JQ et al. Cancer Statistics 2010. CA Cancer J Clin 2010; 60(5): 277–300.

6. Jaarsveld MTM van, Helleman J, Berns EMJJ et al. MicroRNAs in ovarian cancer biology and therapy resistance. Int J Biochem Cell Biol 2010; 42(8): 1282–1290.

7. Salani R, Backes FJ, Fung MFK et al: Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. Am J Obstet Gynecol 2011; 204(6): 466–478.

8. Skates SJ, Mai P, Horick NK et al. Large Prospective Study of Ovarian Cancer Screening in High-Risk Women: CA125 Cut-Point Defined by Menopausal Status. Cancer Prev Res 2011; 4(9): 1401–1408.

9. Záveský L. CA125/MUC16 jako diagnostický a prognostický marker pro karcinom ovaria. Onkologie (Solen) 2012; 6(2): 65–67.

10. Buys SS, Partridge E, Black A et al. Effect of Screening on Ovarian Cancer Mortality The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA 2011; 305(22): 2295–2303.

11. Jacob F, Meier M, Caduff R et al. No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting. Gynecol Oncol 2011; 121(3): 487–491.

12. Iorio MV, Croce CM. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med 2012; 4(3): 143–159.

13. Di Leva G, Croce CM. Roles of small RNAs in tumor formation. Trends Mol Med 2010; 16 (6): 257–267.

14. Scott GK, Mattie ND, Berger CE et al. Rapid alteration of microRNA levels by histone deacetylase inhibition. Cancer Res 2006; 66(3): 1277–1281.

15. Weber JA, Baxter DH, Zhang SL et al. The MicroRNA Spectrum in 12 Body Fluids Clin Chem 2010; 56(11): 1733–1741.

16. Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol 2008; 110(1): 13–21.

17. Bussing I, Slack FJ, Grosshans H. let-7 microRNAs in development, stem cells and cancer. Trends Mol Med 2008; 14(9): 400–409.

18. Brueckner B, Stresemann C, Kuner R et al. The human let-7a-3 locus contains an epigenetically regulated microRNA gene with oncogenic function. Cancer Res 2007; 67(4): 1419–1423.

19. Bendoraite A, Knouf EC, Garg KS et al. Regulation of miR-200 family microRNAs and ZEB transcription factors in ovarian cancer: Evidence supporting a mesothelial-to-epithelial transition. Gynecol Oncol 2010; 116 (1): 117–125.

20. Wu QH, Guo RJ, Lin M, et al. MicroRNA-200a inhibits CD133/1+ ovarian cancer stem cells migration and invasion by targeting E-cadherin repressor ZEB2. Gynecol Oncol 2011; 122(1): 149–154.

21. Resnick KE, Alder H, Hagan JP et al. The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol 2009; 112(1): 55–59.

22. Häusler SFM, Keller A, Chandran PA et al. Whole blood-derived miRNA profiles as potential new tools for ovarian cancer screening. Br J Cancer 2010; 103(5): 693–700.

23. Iorio MV, Visone R, Di Leva G et al. MicroRNA signatures in human ovarian cancer. Cancer Res 2007; 67(18): 8699–8707.

24. Dahiya N, Sherman-Baust CA, Wang TL, et al. MicroRNA Expression and Identification of Putative miRNA Targets in Ovarian Cancer. Plos One 2008; 3(6): e2436.

25. Nam EJ, Yoon HJ, Kim SW et al. MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res 2008; 14(9): 2690–2695.

26. Yang H, Kong W, He L et al. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 2008; 68(2): 425–433.

27. Wyman SK, Parkin RK, Mitchell PS, et al. Repertoire of microRNAs in Epithelial Ovarian Cancer as Determined by Next Generation Sequencing of Small RNA cDNA Libraries. Plos One 2009; 4(4): e5311.

28. Gallagher MF, Flavin RJ, Elbaruni SA, et al. Regulation of microRNA biosynthesis and expression in 2102Ep embryonal carcinoma stem cells is mirrored in ovarian serous adenocarcinoma patients. J Ovarian Res 2009; 2: 19.

29. Laios A, O‘Tooles, Flavin R, et al. Potential role of miR-9 and miR-223 in recurrent ovarian cancer. Mol Cancer 2008; 7: 35.

30. Záveský L, Jančárková N, Kohoutová M. Ovarian cancer: Origin and factors involved in carcinogenesis with potential use in diagnosis, treatment and prognosis of the disease. Neoplasma 2011; 58(6): 457–468.

Paediatric gynaecology Gynaecology and obstetrics Reproduction medicine
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.


Don‘t have an account?  Create new account